Amikacin
- Generic Name
- Amikacin
- Brand Names
- Arikayce, Arikayce liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C22H43N5O13
- CAS Number
- 37517-28-5
- Unique Ingredient Identifier
- 84319SGC3C
- Background
Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A. Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.
...
- Indication
The amikacin sulfate injection is indicated in the short-term treatment of serious bacterial infections due to susceptible strains of gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, as well as Acinetobacter (Mima-Her...
- Associated Conditions
- Bacterial Peritonitis, Bone and Joint Infections, Burns, Central Nervous System Infections, Endophthalmitis, Infection caused by staphylococci, Infective pulmonary exacerbation of cystic fibrosis, Intraabdominal Infections, Meningitis, Bacterial, Mycobacterium avium complex infection, Neonatal Sepsis, Nosocomial Pneumonia, Postoperative Infections, Pulmonary Infections, Respiratory Tract Infection Bacterial, Sepsis Bacterial, Skin and Subcutaneous Tissue Bacterial Infections, Tuberculosis (TB), Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection, Severe Bacterial Infections
- Associated Therapies
- -
" a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA)."
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 26
- Registration Number
- NCT06602557
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 190
- Registration Number
- NCT06585020
- Locations
- 🇫🇷
CHU Amiens-Picardie, Amiens, France
the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 50
- Registration Number
- NCT06097767
- Locations
- 🇪🇬
NICU at Alzahraa University Hospital, Cairo, Egypt
Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 90
- Registration Number
- NCT05761405
- Locations
- 🇨🇭
CHUV, Lausanne, Switzerland
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Rwanda Biomedical Centre
- Target Recruit Count
- 20
- Registration Number
- NCT05555303
- Locations
- 🇷🇼
Kabutare hospital, Kabutare, Rwanda
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Antonios Likourezos
- Target Recruit Count
- 75
- Registration Number
- NCT05227937
- Locations
- 🇺🇸
Maimonides Medical Center, Brooklyn, New York, United States
Amikacin Pharmacokinetics to Optimize Dosing Recommendations in Neonates With Perinatal Asphyxia Treated With Hypothermia
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- University of Sarajevo
- Target Recruit Count
- 80
- Registration Number
- NCT04867993
- Locations
- 🇧🇦
Pediatric Clinic, University Clinical Centre Sarajevo, Sarajevo, Bosnia and Herzegovina
Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT04470973
- Locations
- 🇳🇱
Radboudumc intensive care, Nijmegen, Netherlands
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 300
- Registration Number
- NCT04310930
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)
- Conditions
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2023-04-04
- Target Recruit Count
- 75
- Registration Number
- NCT04209192
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.